The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Characteristics of 9194 Patients With Left Ventricular Hypertrophy: The LIFE Study
Abstract
Abstract —Losartan was the first available orally administered selective antagonist of the angiotensin II type 1 receptor developed for the treatment of hypertension. The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study is a double-blind, prospective, parallel group study designed to compare the effects of losartan with those of the β-blocker atenolol on the reduction of cardiovascular morbidity and mortality. Patients with essential hypertension, aged between 55 and 80 years, and ECG-documented left ventricular hypertrophy (LVH) were included. Altogether, 9223 patients in Scandinavia, the United Kingdom, and the United States were randomized from June 1995 through April 1997, and 9194 remain after exclusion of a study center at which irregularities were discovered. This population of hypertensives (mean systolic/diastolic blood pressure, 174.4/97.8 mm Hg) with LVH comprises women (54.1%) and men, mostly retired from active work (mean age, 66.9 years), with a high prevalence of overweight (mean body mass index, 28.0 kg/m 2 ), diabetes mellitus (12.3%), lipid disorders (18.0%), and symptoms or signs of coronary heart disease (15.1%). There were fewer current smokers (<17%) than in the general population, and ≈7% were nonwhite. Almost 30% of participants had been untreated for at least 6 months when screened for the study. Only 1557 persons who entered the placebo run-in period of 14 days were excluded, predominantly because of sitting blood pressures above or below the predetermined range of 160-200/95-115 mm Hg and ECG-LVH criteria not met. By application of simple 12-lead ECG criteria for LVH (Cornell voltage QRS duration product formula plus Sokolow-Lyon voltage read by a core laboratory), hypertensive patients with LVH with an average 5-year coronary heart disease risk of 22.3% according to the Framingham score were identified. This population is now being treated (goal, <140/90 mm Hg) in adherence with the protocol for at least 4 years after final enrollment (ie, through April 2001) and until at least 1040 patients suffer myocardial infarction, stroke, or cardiovascular death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Self-citationLevy, D., Garrison, R. J., Savage, D. D., Kannel, W. B., & Castelli, W. P. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005313222203 · Cited by 5,699
(1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440420033005 · Cited by 3,777
(1999) · Journal of Hypertension · doi:10.1097/00004872-199917020-00001 · Cited by 3,695
Koren, M. J., Devereux, R. B., Casale, P. N., Savage, D. D., & Laragh, J. H. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-5-345 · Cited by 2,366
Self-citationSokolow, M., & Lyon, T. P. (1949) · American Heart Journal · doi:10.1016/0002-8703(49)90562-1 · Cited by 1,980
Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)
Dahlöf, B., Hansson, L., Lindholm, L. H., Scherstén, B., Ekbom, T., & Wester, P.-O. (1991) · The Lancet · doi:10.1016/0140-6736(91)92589-t · Cited by 1,881
Self-citationAngiotensin II receptors and angiotensin II receptor antagonists.
Timmermans, P. B., Wong, P. C., Chiu, A. T., Herblin, W. F., Benfield, P., Carini, D. J., Lee, R. J., Wexler, R. R., Saye, J. A., & Smith, R. D. (1993) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00446-6 · Cited by 1,853
An updated coronary risk profile. A statement for health professionals.
Anderson, K. M., Wilson, P. W., Odell, P. M., & Kannel, W. B. (1991) · Circulation · doi:10.1161/01.cir.83.1.356 · Cited by 1,834
Coleman, R. A., Smith, W. L., & Narumiya, S. (1994) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06784-5 · Cited by 1,735
Pitt, B., Segal, R., Martinez, F. A., Meurers, G., Cowley, A. J., Thomas, I., Deedwania, P. C., Ney, D. E., Snavely, D. B., & Chang, P. I. (1997) · The Lancet · doi:10.1016/s0140-6736(97)01187-2 · Cited by 1,665
Casale, P. N., Devereux, R. B., Alonso, D. R., Campo, E., & Kligfield, P. (1987) · Circulation · doi:10.1161/01.cir.75.3.565 · Cited by 561
Self-citationSchieffer, B., Wirger, A., Meybrunn, M., Seitz, S., Holtz, J., Riede, U. N., & Drexler, H. (1994) · Circulation · doi:10.1161/01.cir.89.5.2273 · Cited by 420
Molloy, T. J., Okin, P. M., Devereux, R. B., & Kligfield, P. (1992) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(92)90376-x · Cited by 407
Self-citationOkin, P. M., Roman, M. J., Devereux, R. B., & Kligfield, P. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(94)00371-v · Cited by 395
Self-citationSever, P., Beevers, G., Bulpitt, C., Lever, A., Ramsay, L., Reid, J., & Swales, J. (1993) · BMJ · doi:10.1136/bmj.306.6883.983 · Cited by 355
Self-citationLiao, Y. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03520440046035 · Cited by 325
(1997) · American Journal of Hypertension · doi:10.1016/s0895-7061(97)00054-x · Cited by 307
Goldberg, A. I., Dunlay, M. C., & Sweet, C. S. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80413-5 · Cited by 270
&NA;, &. (1993) · Journal of Hypertension · doi:10.1097/00004872-199309000-00004 · Cited by 267
Zanchetti, A., Chalmers, J. P., Arakawa, K., Gyarfas, I., Hamet, P., Hansson, L., Julius, S., MacMahon, S. W., Mancia, G., Ménard, J., et al. (1993) · Journal of Hypertension · Cited by 245
Self-citationHow smoking affects blood pressure
Omvik, P. (1996) · Blood Pressure · doi:10.3109/08037059609062111 · Cited by 234
Self-citationNorman, J. E., & Levy, D. A. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00269-5 · Cited by 112
Gender Differences and the Electrocardiogram in Left Ventricular Hypertrophy
Okin, P. M., Roman, M. J., Devereux, R. B., & Kligfield, P. (1995) · Hypertension · doi:10.1161/01.hyp.25.2.242 · Cited by 99
Self-citationHansson, L., & Zanchetti, A. (1994) · Blood Pressure · doi:10.3109/08037059409102281 · Cited by 84
Mundal, R., Kjeldsen, S. E., Sandvik, L., Erikssen, G., Thaulow, E., & Erikssen, J. (1997) · Journal of Hypertension · doi:10.1097/00004872-199715030-00005 · Cited by 47
Self-citationAngiotensin II Receptor Antagonist Markedly Reduces Mortality in Salt-Loaded Dahl S Rats
von Lutterotti, N., Camargo, M. J. F., Mueller, F. B., Timmermans, P. B. M. W. M., & Laragh, J. H. (1991) · American Journal of Hypertension · doi:10.1093/ajh/4.4.346s · Cited by 24
Cited by
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Self-citationLindholm, L. H., Ibsen, H., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S. E., Kristiansson, K., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08090-x · Cited by 1,560
Self-citationPrognostic Significance of Left Ventricular Mass Change During Treatment of Hypertension
Devereux, R. B. (2004) · JAMA · doi:10.1001/jama.292.19.2350 · Cited by 881
Self-citationWachtell, K., Lehto, M., Gerdts, E., Olsen, M. H., Hornestam, B., Dahlöf, B., Ibsen, H., Julius, S., Kjeldsen, S. E., Lindholm, L. H., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.10.068 · Cited by 826
Self-citation
Metadata
- Authors
- Dahlöf, B., Devereux, R. B., Julius, S., Kjeldsen, S. E., Beevers, G., de Faire, U., Fyhrquist, F., Hedner, T., Ibsen, H., Kristianson, K., Lederballe-Pedersen, O., Lindholm, L. H., Nieminen, M. S., Omvik, P., Oparil, S., & Wedel, H.
- Venue
- Hypertension
- Published
- 1998-12
- Volume
- 32
- Issue
- 6
- Pages
- 989-997
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2140534450
- Cited by
- 294
- References
- 28
- FWCI
- 12.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.